Indications |
Oral Overactive bladder Adult: For symptomatic treatment of urge incontinence, urinary frequency and urgency. Initial: 7.5 mg once daily; may increase dose to 15 mg once daily if no adequate response after 2 wk of therapy. Hepatic impairment: Moderate hepatic impairment (Child Pugh B): Maximum daily dose is 7.5 mg. Severe hepatic impairment (Child Pugh C): Not recommended. |
Contraindications |
Patient with urinary retention, gastric retention, uncontrolled narrow-angle glaucoma, and in patients who are at risk for these conditions. |
Warnings / Precautions |
Anticholinergic agents including Darifenacin, may cause urinary retention and decreased GI motility. Caution when used in patients with clinically significant bladder outflow obstruction, GI obstructive disorder (e.g. pyloric stenosis), severe constipation, ulcerative colitis, and myasthenia gravis. For patients being treated for narrow-angle glaucoma, caution and only use where potential benefits outweigh the risks. May cause heat prostration when used in a hot environment. May cause dizziness and blurred vision; caution when operating machinery or driving vehicle. Not recommended in severe hepatic impairment. Safety and efficacy have not been established in paediatric patients. Pregnancy and lactation. |
Adverse Reactions |
Dry mouth, nausea, abdominal pain, constipation, diarrhoea, dyspepsia, dizziness, headache, asthaenia, pain, weight gain, dry skin, rash, pruritus, dry eyes, abnormal vision, arthralgia, bronchitis, pharyngitis, rhinitis, sinusitis, flu-like syndrome, UTI, vaginitis, acute urinary retention, hypertension and peripheral oedema. Potentially Fatal: Hypersensitivity reactions, including angioedema. |
Overdose Reactions |
Symptoms: May cause severe antimuscarinic effects; abnormal vision has been reported. Treatment: Monitor ECG and provide symptomatic and supportive treatment. |
Drug Interactions |
Concurrent use of CYP3A4 inhibitors (e.g. ketoconazole, itraconazole, clarithromycin, nefazodone, troleandomycin, ritonavir, nelfinavir) or CYP2D6 inhibitors (e.g. quinidine, paroxetine) may increase serum levels of Darifenacin. CYP3A4 inducers (e.g. barbiturates, phenytoin, rifampicin) may likely decrease Darifenacin serum concentrations. Darifenacin may act as a moderate inhibitor of CYP2D6, caution when used concomitantly with CYP2D6 substrates that have narrow therapeutic index (e.g. flecainide, thioridazine, imipramine). Concurrent use of another agent with antimuscarinic properties may potentiate the side effects of Darifenacin. See Below for More darifenacin Drug Interactions |
Food Interactions |
Avoid grape fruit juice, may increase levels of Darifenacin. St John's wort may decrease Darifenacin levels. |
Mechanism of Actions |
Darifenacin is a potent, competitive and selective muscarinic receptor antagonist which has greater binding affinity for muscarinic M3 receptors. M3 receptors are involved in the contraction of the detrusor muscle of the bladder, GI smooth muscle, saliva production, and iris sphincter function. Darifenacin may increase volume threshold in patients with involuntary detrusor contraction, thus increase bladder capacity. Absorption: Tmax: About 7hr. Steady-state plasma concentrations reached within 6th day of dosing. Bioavailability: About 15% (for 7.5 mg tab) and 19% (for 15 mg tab). Distribution: Protein binding: About 98% (mainly to α1-acid glycoproteins). Vd: About 163 L. Metabolism: Extensive hepatic metabolism mainly by CYP3A4 and CYP2D6. Metabolism in individuals who are poor metaboliser (PMs) of CYP2D6 will be principally mediated by CYP3A4. Excretion: Urine (about 60%) and faeces (about 40%). Elimination half-life: About 13-19 hr. |
Administration |
May be taken with or without food. (Swallow whole, do not chew/crush/divide.) |
Storage Conditions |
Oral: Store at 25°C (77°F); excursions permitted 15-30°C (59-86°F). Protect from light. |
ATC Classification |
G04BD10 - darifenacin ; Belongs to the class of urinary antispasmodics. |
Storage |
Oral: Store at 25°C (77°F); excursions permitted 15-30°C (59-86°F). Protect from light. |
Available As |
|
Darifenacin
Post Review about Darifenacin Click here to cancel reply.
Darifenacin Containing Brands
Darifenacin is used in following diseases
Drug - Drug Interactions of Darifenacin
Latest News
- FDA approves Ruconest for treatment of hereditary angioedema
- FDA recommend against aspirin to prevent First Heart Attacks
- FDA approves Pomalyst (pomalidomide) for advanced multiple myeloma
- FDA approves three new drug treatments for type 2 diabetes
- Long-term consequences of vaginal delivery on the pelvic floor
No comments yet.